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Objectives: To investigate the incidence, treatment and outcome of breakthrough invasive fungal infections (IFIs)
in adult acute myeloid leukaemia (AML) patients after posaconazole prophylaxis.
Methods: From January 2010 to April 2012, all consecutive patients with newly diagnosed AML were prospect-
ively registered at 33 participating Italian centres. All cases of IFIs occurring within 30 days after the end of the
first induction chemotherapy were recorded. The strategy of antifungal treatment (empirical, pre-emptive or tar-
geted) and the drugs used were analysed. ClinicalTrials.gov code: NCT01315925.
Results: In total, 1192 patients with newly diagnosed AML were enrolled in the study, of whom 510 received
posaconazole prophylaxis and were included in the present analysis. Of these patients, 140 (27%) needed sys-
temic antifungal treatment. Among the 127 evaluable cases, an empirical approach was utilized in 102 patients
(80%), a pre-emptive approach in 19 patients (15%) and targeted therapy in 6 patients (5%). Only five patients
died of IFIs (three in the empirical group and two in the targeted group; 4%). A critical review of IFI diagnoses at
30 days demonstrated that among the patients treated empirically, 30% were not affected by IFIs but rather
only by fever of unidentified origin. A comparison between the empirical and the pre-emptive groups showed no
significant differences regarding the attributable and overall mortalities.
Conclusions: This study confirms that posaconazole prophylaxis reduces the incidence of breakthrough IFIs
and does not modify the efficacy of subsequent systemic antifungal treatment, regardless of the approach
(empirical or pre-emptive) or the antifungal drug used.
Keywords: antifungal prophylaxis, acute myeloid leukaemia, empirical therapy
Introduction
Prophylaxis with posaconazole is currently a well-defined form of
therapeutic strategy, characterized by a reduction in overall inva-
sive fungal infections (IFIs) and specifically of infections due to
Aspergillus spp. This reduction has been demonstrated both by
clinical trials1,2 and by many actual clinical experiences.3 – 6
However, although therewas a significant reduction in the propor-
tion of proven/probable IFIs in all of these studies, a consistent
proportion of patients (30%) still needed subsequent systemic
antifungal treatment. This need may be due to breakthrough
IFIs or to a delay in the positivity of microbiological diagnostic
tests. Furthermore, the most correct therapeutic approach
(empirical or pre-emptive) and the most effective antifungal
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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drugs are not yet established in the setting of posaconazole
prophylaxis failure.
In this prospective, multicentre, non-randomized, observa-
tional study, we analysed the behaviour of Italian haematologists
in cases of suspected failure of posaconazole prophylaxis and the
outcome of patients with breakthrough IFIs.
Patients and methods
This prospective study was conducted in 33 haematology wards in tertiary
care centres or university hospitals located throughout Italy from 1 January
2010 to 30 April 2012. All consecutive, newly diagnosed adult patients with
acute myeloid leukaemia (AML) undergoing first remission induction by
chemotherapy who received posaconazole prophylaxis were included in
the registry and followed up. Data were prospectively entered into case
report forms. ClinicalTrials.gov code: NCT01315925.
Posaconazole was administered at a dose of 200 mg thrice daily. The
treatment was started at 1–2 days prior to cytoreductive chemotherapy
and continued until neutrophil recovery to.0.5×109/L, the occurrence of
a confirmed or suspected IFI or drug-related toxicity/intolerance.
The SEIFEM registry was approved by the Ethics Committees of the
participating sites. Written informed consent was obtained from all
participants.
Given the non-interventional nature of the study, enrolling a patient in
the registry had no impact on the standard clinical practice of each
haematology unit.
The follow-up of the last patient was completed on 31 August 2012. A
minimum follow-up of 12 weeks after the completion of chemotherapy
was requested.
For each patient, baseline data were recorded at the time of admission
(age, gender, AML subtype and AML treatments). The registry also included
data regarding the antifungal therapy, as follows: employed drugs, dos-
age, type of approach (e.g. empirical, pre-emptive or targeted treatment)
and duration of antifungal treatment.
The diagnostic work-up included the following: nasal, pharyngeal and
rectal swabs at the time of admission; blood cultures and chest X-rays at
the onset of fever; galactomannan assays once or twice per week; and
chest computed tomography (CT) scan on days 4–7 of fever. Additional
examinations (e.g. an abdominal ultrasound scan, a sinus or brain CT, a
skin biopsy, bronchoalveolar lavage and fundus examination) were per-
formed as required.
The IFI incidence within the first 30 days from the end of chemother-
apy was assessed. IFIs were classified in accordance with the new 2008
European Organisation for Research and Treatment of Cancer/Mycoses
Study Group (EORTC/MSG) criteria.7 Proven IFIs were considered when fun-
gal elements in diseased tissue were demonstrated. Probable IFIs were
defined when host factors (in our series all patients were AML in induction
phase), clinical signs, radiological pictures and a positive microbiological
test (i.e. galactomannan test) were present.
Mortality due to IFIs (IFI-attributable mortality) was considered when
patients died within 12 weeks after the onset of fever and had microbio-
logical, histological or clinical evidence of an active IFI if other potential
causes of death could be excluded by the physician responsible.8
All causes of death within 12 weeks were recorded (overall mortality).
Statistical analysis
Continuous variables were compared using Student’s t-test (normally
distributed variables) or the Mann–Whitney U-test (non-normally dis-
tributed variables). Categorical variables were evaluated using the x2
or two-tailed Fisher’s exact test. Values are expressed as the mean+
standard deviation or the median (range) (continuous variables) or as
a percentage of the group from which they were derived (categorical
variables).
Two-tailed tests were used to determine statistical significance.
A P value of ,0.05 was considered significant. All statistical analyses
were performed with the Intercooled Stata program, version 11, for
Windowsw (Stata Corporation, College Station, TX, USA).
Results
Over a 28 month period, 1192 adult patients with newly diag-
nosed AML were enrolled in the study at 33 participating centres.
In total, 211 patients received only low-dose therapies or pallia-
tive treatments and were excluded from the present analysis.
The present analysis focused on the remaining 981 AML
patients who received conventional intensive chemotherapy. Of
these patients, 545 were male and 436 were female and the
mean age was 55 years (range 18–84). In 746 cases, induction
treatment was anthracycline based and in 173 patients the treat-
ment was fludarabine based. Additionally, 43 patients were
treatedwith high doses of cytosine arabinoside and in the remain-
ing 19 cases miscellaneous aggressive treatments were adminis-
tered (Figure 1).
A total of 510 patients received posaconazole prophylaxis dur-
ing post-chemotherapy aplasia. Among these patients, nine who
received,5 days of posaconazole (early death for AML) were not
considered as eligible for the study. No clinical adverse event or
laboratory abnormality (WHO .3) attributed to posaconazole
and causing a discontinuation of prophylaxis was observed in
the remaining patients.
In total, 140 of 510 evaluable patients (27%) needed systemic
antifungal therapy. Among these patients, 13 were excluded from
analysis because they received treatment for ,7 days: 6 due
to early death from AML and 1 due to early death from IFIs
(1 Pneumocystis jirovecii pneumonia). Additionally, six of the
patients were evaluated as having no fungal infection and conse-
quently received ,7 days of antifungal therapy.
1192 consecutive, newly diagnosed AML patients 
981 patients were treated with aggressive chemotherapy
510 patients received posaconazole prophylaxis
102 (80%) empirical 19 (15%) pre-emptive 6 (5%) targeted
140 (27%) needed systemic antifungal therapy
127 evaluable patients started treatment











Among the remaining 127 patients, 102 (80%) started antifun-
gal treatment as an empirical approach and 19 patients (15%)
started treatment as a pre-emptive approach. Only six patients
(5%) received a targeted treatment. The main characteristics of
the three groups are reported in Table 1.
Antifungal treatment was started based on well-established
criteria,9 as follows: empirical approach (based only on host fac-
tors plus fever unresponsive to extensive antibiotic treatment);
pre-emptive approach (IFI diagnosis suspected due to microbio-
logical factors or clinical factors); and targeted treatment (proven
diagnosis according to the EORTC-MSG criteria).
Thirty days from the start of antifungal treatment, a critical
review of IFI diagnosis was performed to verify the propriety of
the diagnosis.
A total of 90 IFIs were diagnosed. According to the EORTC
criteria, these infections consisted of 62 possible, 18 probable
and 10 proven IFIs. Among these infections, only four cases (all
proven) were due to yeasts (three Candida strains and one
Trichosporon strain). All of the other 86 IFIs were considered to
be due to invasive aspergillosis (IA). No cases of rare moulds (i.e.
mucormycosis or fusariosis) were diagnosed or suspected. Of
note, at the time of the critical review of the diagnosis at
30 days, 37 cases (29%) remained classified as fever of unidenti-
fied origin (FUO) without evidence of an IFI.
The IFI-attributable mortality rate at 12 weeks was 4% (5/127
cases: 2 possible IA, 1 probable IA and 2 candidaemia) and overall
mortality was 27% (34/127 cases). These percentages were 5.5%
(5/90) and 38% (34/90), respectively, excluding the 37 cases
reclassified as FUO at 30 days revision.
Empirical treatment
The majority of patients started an empirical antifungal approach
(102/127, 80%). The most utilized antifungal drug was liposomal
amphotericin B (L-AmB), administered to 69 patients (68% of
cases). At 30 days of follow-up, a review of L-AmB-treated patients
indicated 37 cases of possible IA, 4 cases of probable IA and2 cases
of proven IA, whereas in 26 cases the diagnosis remained FUO.
The second most frequently utilized antifungal drug was
caspofungin, administered to 26 patients. The same review per-
formed at 30 days showed possible IA in 12 patients and probable
IA in 5 patients. Nine patients had FUO.
Four of the remaining seven patients received amphotericin B
lipid complex (ABLC) and three received voriconazole. At 30 days,
five cases were defined as possible IA (two treated with ABLC and
three with voriconazole) and two, treated with ABLC, were consid-
ered as only FUO.
Three patients (3%), all in the L-AmB group, died from IFIs (two
cases treated for possible IA and one treated for probable IA). Of
note, the two patients with proven IA recovered from infection.
The overall mortality at 12 weeks among these patients was
25% (26/102).
Pre-emptive treatment
Nineteen patients were treated based on a positive diagnostic
work-up. All patients presented a positive galactomannan test with
clinical and radiological signs compatible with IA. L-AmB was admi-
nistered to 12 patients: for possible IA in 5 cases and probable IA in 7
cases. Voriconazole was administered to four patients for possible IA
and to two patients for probable IA. One patient with possible IAwas
treated with a therapeutic dose of posaconazole (400 mg×2). Thirty
days fromthe start of treatment, a critical reviewof thediagnosiswas
performed and two probable cases treated with voriconazole were
observed to have become proven IA. No death due to an IFI was
observed. The overall mortality at 12 weeks among these patients
was 21% (4/19).
The distribution of patients subject to the different systemic
antifungal empirical or pre-emptive approaches or to targeted
treatments is reported in Table 2.
Targeted treatment
In all cases, treatment was started when a proven diagnosis was
made in three candidaemia, one Trichosporon fungaemia and two
IA cases. The three patients with candidaemia (one Candida
Table 1. Main characteristics of patients who received systemic antifungal therapy after posaconazole prophylaxis, evaluation of the distribution of
certain levels of invasive fungal disease 30 days from the start of treatment and comparison between the empirical and the pre-emptive approaches
Empirical (n¼102) Pre-emptive (n¼19)
Comparison of empirical
versus pre-emptive (P) Targeted (n¼6)
Age (years), mean (range) 55 (18–79) 58 (44–72) 0.2 57 (47–74)
Male/female, n/n 55/48 12/7 0.45 3/3
Duration of previous prophylaxis (days), mean (range) 22 (6–150) 24 (6–120) 0.8 18 (8–27)
Duration of neutrophils ,500/mm3 (days), mean (range) 21 (6–48) 17 (8–38) 0.06 21 (15–30)
Treatment duration (days), mean (range) 13 (12–14) 18 (13–23) 0.04 22 (15-35)
Follow-up of invasive fungal disease at 30 days
FUO 37 — —
possible 54 10 —
probable 9 7 —
proven 2 2 6a
IFI-attributable mortality, n (%) 3 (3) 0 0.5 2 (33)
Overall mortality at 12 weeks, n (%) 26 (25) 4 (21) 0.2 4 (66)
aThree candidaemia, one Trichosporon fungaemia and two invasive aspergillosis.











glabrata, one Candida krusei and one Candida albicans) received
caspofungin in two cases (one recovered and one died of infec-
tion) and voriconazole in one case (died of infection). The patient
with Trichosporon was treated with voriconazole and recovered
from infection. The remaining two patients, with IA, were each
treated with L-AmB and ABLC and recovered from infection. The
attributable mortality rate was 33% (2/6 patients) and overall
mortality at 12 weeks among these six patients was 67% (4/6).
Univariate analysis
Patients treated with one of the two different strategies, empirical
or pre-emptive, were compared and the results are reported in
Table 1. A significant difference was observed between groups
only for the treatment duration, which was longer in the pre-
emptive group (18 days versus 13 days, P,0.04). A trend was
observed for neutropenia duration (P¼0.06), which was longer
in the empirical approach (21 days versus 17 days). No significant
differences were observed for the attributable mortality rate or
overall mortality between the two groups. Even excluding cases
of FUO in the empirical treatment group (37 patients), no signifi-
cant difference regarding attributable mortality was observed
between the two groups (data not shown).
In the empirical group, a comparison between L-AmB and
caspofungin, the two most utilized agents, was not statistically
significant.
Discussion
The introduction of prophylaxis with posaconazole has changed
the epidemiology of IFIs in patients with haematological malig-
nancies. In fact, various actual clinical experiences have con-
firmed the results of clinical trials documenting an important
reduction in the incidence of IFIs in patients with AML and in
patients undergoing allogeneic stem cell transplantation.1 – 6
However, this type of prophylaxis has also reduced the efficacy
of certain microbiological diagnostic tools that previously seemed
absolutely predictive (i.e. serum galactomannan).10,11
In general, the new scenario that we are facing is a reduction in
the IFI burden. However, when a breakthrough IFI is suspected
during posaconazole prophylaxis, there is less diagnostic cer-
tainty. How to treat this patient? The IDSA guidelines seem to
be clear:12 if the patient receives mould-active prophylaxis, the
use of an empirical approach is preferable and the class of anti-
fungal agent for treatment should be switched. Therefore, given
that posaconazole is an azole, voriconazole therapy would not
be indicated. The second question that arises is whether after
prophylaxis with posaconazole, select fungal strains, and espe-
cially Aspergillus spp., are unresponsive to subsequent systemic
antifungal treatment with other non-azole drugs? A number of
studies, including one recently published by De la Serna et al.13
in Spain, show that previous mould-active antifungal prophylaxis,
including posaconazole, does not change susceptibility to treat-
ment with L-AmB.14
Our study, conducted on a large and homogeneous series of
patients with AML undergoing first-line chemotherapy treatment
for remission induction, confirms that the need for systemic
antifungal therapy after oral posaconazole prophylaxis has signifi-
cantly decreased in patientswith AML. This decline has progressed
from 50%–60%, as reported several years ago in the pre-
posaconazole era, to,30%, reported in the current posaconazole
era.6 Our experience is in line with all the recent real-life experi-
ence regarding posaconazole prophylaxis.15
In clinical practice today, perhaps more than ever, we observe
a greater tendency to use an empirical antifungal strategy. In fact,
.80% of our patients have been treated with this approach.
However, comparing data regarding IFI-attributable mortality
between the empirical and the pre-emptive therapies, we did
not confirm the results of the Hema e-Chart study, although
only 2 years elapsed between the two studies.16 In the Hema
e-Chart study, it was shown that empirical therapy, regardless
of the type of systemic antifungal treatment, resulted in a
Table 2. Distribution of patients in the different groups of systemic antifungal treatments
Type of evidence/
drug (cases)
Diagnosis of invasive fungal disease
at 30 days






Empirical (102) 14 (6–90) 3 (3) 26 (25)
L-AmB (69) FUO (26) 13 (6–40) 3 15
possible (37)
probable (6)
caspofungin (26) FUO (9) 11 (14–58) — 9
possible (12)
probable (5)
other (7) (4 ABLC,
3 voriconazole)
FUO (2) 11 (7–19) — 2
possible (5)
Pre-emptive (19) 18 (8–42) 0 4 (21)
L-AmB (12) possible (5) 15 (8–30) — 2
probable (7)
voriconazole (6) possible (4) 23 (10–42) — 1
probable (2)











significant reduction in IFI-attributable mortality compared with
pre-emptive treatment. This discrepancy is likely due to the com-
pletely different type of prophylaxis used in the Hema e-Chart
study (no prophylaxis or non-mould-active azoles, such as flucon-
azole or itraconazole), which is less effective than posaconazole
prophylaxis, and to the narrow selection criteria for the cohort
of patients in the present study (only AML in the induction
phase). All of these factors could explain why we could not con-
firm the previously observed significant difference in mortality
between patients treated empirically and patients treated pre-
emptively in the present study. On the other hand, it must be
taken into account that the small number of patients treated
with pre-emptive therapy limits the comparison with the empir-
ical group.
Another important issue is the possible difference in the efficacy
between caspofungin and L-AmB in the empirical approach.
A study by Walsh et al.17 has already shown that in empirical anti-
fungal therapy, these two drugs were equivalent. However, subse-
quent studies by Viscoli et al.18 andHerbrecht et al.19 demonstrated
the unsatisfactory efficacy of caspofungin in the case of a targeted
therapy for IA, requiring reconsideration of the role of caspofungin
against IA in patientswith haematologicalmalignancies. Our study
was not a randomized trial or a large enough series to be able to
reach definitive conclusions on this topic. However, our study
shows that even in the era of posaconazole prophylaxis, there are
no differences in favour of either drug.
When we analysed the different drugs used in the pre-emptive
approach, no difference was observed between L-AmB and vori-
conazole treatments. Of note, no IFI-attributable deaths were
observed in the voriconazole arm. This could be due to the
small number of patients (only six cases) treated with voricon-
azole. However, the previous posaconazole prophylaxis does not
seem to have changed the response to voriconazole treatment.
Interestingly, among our patients, beyond the case of
fungaemia due to Trichosporon, there were no cases of other
rare fungal agents and no breakthrough mucormycosis was
documented. Overall IFI-attributable mortality was only 5.5%,
showing that previous prophylaxis with posaconazole did not
affect the subsequent course of the fungal infection.
Furthermore, our study confirmed the decreasing trend in the
attributable mortality rate that was already observed in our
previous epidemiological studies.20,21 Thanks to the available
systemic antifungal treatments, at present, mortality due to
invasive fungal diseases in patients with haematological malig-
nancies treated with conventional chemotherapy is ,20%. In
particular, in AML, during the first induction of remission, mortal-
ity is lower than in other phases not only due to antifungal
prophylaxis and treatments but also due to improvements in
recent years in supportive care.
Our study confirmed one last important point. A significant
percentage of patients (37/127, 29%) initially with antifungal
therapy subsequently had no evidence of an IFI. This finding
means that in at least one-third of patients who are receiving
empirical antifungal therapy, the antifungal treatment is probably
unnecessary and started in an inappropriate manner, basedmore
on an emotional driver than on a scientific process. However, we
cannot exclude the possibility that empirical treatment can clear
an undetectable fungal infection.
In conclusion, this observational study of a large number of
AML patients allows us to understand current practice in
antifungal treatment after failure of posaconazole prophylaxis.
The introduction of this prophylaxis has led to a marked reduction
in the incidence of IFIs. In our study about one-third of patients
undergoing antifungal prophylaxis needed treatment with sys-
temic antifungals, however this rate could have been markedly
reduced because most of the patients were finally defined as
affected by FUO and not by true fungal infections. Posaconazole
has not had a negative impact on subsequent treatment in cases
of failure of prophylaxis. However, our findings have highlighted
the need for more specific diagnostic tools, particularly to reduce
the 30% of antifungal treatments that are unnecessary.
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